Abstract
Purpose
Surgical site infections (SSIs) occur more frequently in surgery for patients with ulcerative colitis than in regular colon surgery. We report here on a joint study that was prospectively conducted by six facilities to verify that performing leukocytapheresis (LCAP) therapy immediately following surgery regulates neutrophil activity and acts to suppress the occurrence of SSIs.
Methods
LCAP was performed using Cellsorba EX with nafamostat mesilate as an anticoagulant; therapy was begun within 2 h postoperatively. Subjects were 143 patients undergoing surgery in cases of ulcerative colitis (LCAP group, 40 patients; control group, 103 patients).
Results
1) With regard to the SSI incidence rate, SSIs occurred in 4 of 37 patients (10.8%) in the LCAP group overall, whereas they occurred in 29 of 103 patients (28.2%) in the control group overall; in the LCAP group, the occurrence of SSIs tended to be suppressed (P = 0.069). With 2-stage surgery in particular, SSIs occurred in the LCAP group in 1 of 28 patients (3.6%) and in the control group in 21 of 86 patients (24.4%); in the LCAP group, the occurrence of SSIs was significantly lower (P = 0.013). The length of postoperative hospitalization was 24.9 ± 11.1 days for the 36 patients in the LCAP group and 31.2 ± 14.6 days for the 103 patients in the control group; the length was significantly reduced in the LCAP group (P = 0.018). 2) From pre-surgery to day 1 of hospitalization, the granulocyte elastase level rose both in patients who experienced SSIs and in patients who did not experience them. It remained high in patients who experienced SSIs in comparison with patients who did not experience SSIs and was significantly higher prior to LCAP in particular. 3) While LCAP was being performed, there were adverse events in 5 of 40 patients (12.5%), but these were all transient; it was determined that LCAP presented no problems in terms of safety.
Conclusion
LCAP therapy was effective in suppressing the occurrence of SSIs following 2-stage surgery for ulcerative colitis and also reduced the length of postoperative hospitalization.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for he Prevention of Surgical Site Infection. Infect Cont Hosp Epidemiol 1999;20:247–278.
Harihara Y, Konishi T. Surgeon’s concern to surgical site infection: Effectiveness of SSI surveillance (in Japanese). Shokakigeka 2003;26:1193–1200.
Takesue Y, Kusunoki M, Kobayashi M, Kono T, Ebisawa Y, Watanebe T, et al. The prevalence of surgical site infection (SSI) by the introduction of the best practice in the perioperative management and operative manipulation; multi-center prospective study of 1,601 colorectal patients (in Japanese with English abstract). Nihon Geka Kansensho Gakkaizasshi (J Jpn Soc Surg Infect) 2006;3(4):471–476.
Itabashi M, Yoshimura Y, Suenaga K, Bamba Y, Takemoto K, Yamada A, et al. Surgical site infection after pouch operation for ulcerative colitis (in Japanese with English abstract). Nihon Geka Kansensho Gakkaizasshi (J Jpn Soc Surg Infect) 2006;3(2):161–165.
Sawada K, Muto T, Shimoyama T, Satomi M, Sawada T, Nagawa H. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003;9:307–321.
Kanai T, Hibi T, Watanabe M. The logic of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opin Biol Ther 2006;6(5):453–466.
Imamura Y, Takesue Y, Sueda T. Changes in neutrophil functions in the early stage of systemic inflammation following surgical intervention (in Japanese with English abstract). Nihon Geka Kansensho Gakkaizasshi (J Jpn Soc Surg Infect) 2006;3(2):147–153.
Miki C, Yoshiyama S, Ohkita Y, Araki T, Uchida K, Kusunoki M. Strategy development for preventing postoperative infectious complication in patients with ulcerative colitis (in Japanese). Geka 2006;68(9):1012–1017.
Hirayama K, Koyama T. Adverse events of plasma exchange (in Japanese). Nihon Rinsho (Nippon rinsho) 2004;62suppl 5:319–322.
Yamamori Y, Saito Y, Hashimoto K, Sakura S, Uchida H, Kosaka Y. Evaluation of plasmapheresis for autoimmune neuromuscular diseases (in Japanese with English abstract). ICU to CCU (ICU & CCU) 1997;21(8):737–741.
Agishi T, Iwai T, Ishimaru S, Amano I, Azuma N. Cooperative multiinstitutional evaluation study of apheresis treatments for arteriosclerosis obliterans in the lower limbs without hyperlipidemia (in Japanese with English abstract). Nihon Apheresis Gakkaizasshi (Jpn J Apher) 2006;25(1):42–51.
Shimizu M, Tsuda H, Sanaka T, Ide K. Present status of therapeutic apheresis in Japan: survey report. Ther Apher 1998;2(3):172–181.
Klingel R, Fassbender C, Fassbender T, Göhlen B. Clinical studies to implement rheopheresis for age-related macular degeneration guided by evidence-based-medicine. Transfus Apheresis Sci 2003;29:71–84.
Miki C, Yoshiyama S, Okita Y, Araki T, Uchida K, Yanagi H, et al. Neutrophil priming as a surgery-related risk factor for postoperative infectious complications in patients with ulcerative colitis. Dig Surg 2006;23:179–185.
Ogawa R. Surgical injury and SIRS: Modification by anesthesia (in Japanese). Kyukyuigaku (Jpn J Acute Med) 1996;20:1099–1104.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Itabashi, M., Ikeuchi, H., Araki, T. et al. Effectiveness of leukocytapheresis in suppressing the occurrence of surgical site infections following surgery for ulcerative colitis. Surg Today 38, 609–617 (2008). https://doi.org/10.1007/s00595-007-3685-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00595-007-3685-3